Plasma Amyloid-β Oligomerization Tendency Predicts Amyloid PET Positivity

References

• Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207–216.23332364
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012;367:795–804.22784036
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dement. 2018;14:535–562.29653606
   PubMed Web of Science ®Google Scholar
• Pyun J-M, Kang MJ, Ryoo N, et al. Amyloid metabolism and amyloid-targeting blood-based biomarkers of Alzheimer’s Disease. J Alzheimer’s Dis. 2020;75:685–696.32390633
   PubMed Web of Science ®Google Scholar
• An SSA, Lee BS, Yu JS, et al. Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42. Alzheimer’s Res Ther. 2017;9:86.29041968
   PubMed Web of Science ®Google Scholar
• Youn YC, Lee BS, Kim GJ, et al. Blood Amyloid-β oligomerization as a biomarker of Alzheimer’s disease: a blinded validation study. J Alzheimer’s Dis. 2020;75:493–499.32310175
   PubMed Web of Science ®Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:263–269.21514250
   PubMed Web of Science ®Google Scholar
• Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011;7:270–279.21514249
   PubMed Web of Science ®Google Scholar
• Jessen F, Amariglio RE, Van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s Dement. 2014;10:844–852.24798886
   PubMed Web of Science ®Google Scholar
• Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–2477.21810890
   PubMed Web of Science ®Google Scholar
• Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–1014.21325651
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.23359374
   PubMed Web of Science ®Google Scholar
• Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the Movement Disorder Society Task Force. Mov Disord. 2007;22:2314–2324.18098298
   PubMed Web of Science ®Google Scholar
• Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology. 1996;47:1–9.8710059
   PubMed Web of Science ®Google Scholar
• Toledo JB, Vanderstichele H, Figurski M, et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol. 2011;122:401–413.21805181
   PubMed Web of Science ®Google Scholar
• Serem WK, Bett CK, Ngunjiri JN, et al. Studies of the growth, evolution, and self-aggregation of β-amyloid fibrils using tapping-mode atomic force microscopy. Microsc Res Tech. Microsc Res Tech. 2011;74:699–708.21698718
   PubMed Web of Science ®Google Scholar
• Kuo YM, Emmerling MR, Lampert HC, et al. High levels of circulating Aβ42 are sequestered by plasma proteins in Alzheimer’s disease. Biochem Biophys Res Commun. 1999;257:787–791.10208861
   PubMed Web of Science ®Google Scholar
• Cline EN, Bicca MA, Viola KL, et al. The Amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimer’s Dis. 2018;64:S567–S610.29843241
   PubMed Web of Science ®Google Scholar
• Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimer’s Dement. 2017;13:841–849.28734653
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature. 2018;554:249–254.29420472
   PubMed Web of Science ®Google Scholar
• Verberk IMW, Slot RE, Verfaillie SCJ, et al. Plasma amyloid as prescreener for the earliest alzheimer pathological changes. Ann Neurol. 2018;84:648–658.30196548
   PubMed Web of Science ®Google Scholar
• Vergallo A, Mégret L, Lista S, et al. Plasma amyloid β 40/42 ratio predicts cerebral amyloidosis in cognitively normal individuals at risk for Alzheimer’s disease. Alzheimer’s Dement. 2019;15:764–775.31113759
   PubMed Web of Science ®Google Scholar
• Nabers A, Ollesch J, Schartner J, et al. Amyloid-β-Secondary structure distribution in cerebrospinal fluid and blood measured by an immuno-infrared-sensor: a biomarker candidate for Alzheimer’s disease. Anal Chem. 2016;88:2755–2762.26828829
   PubMed Web of Science ®Google Scholar
• Güldenhaupt J, Brenner H, Janelidze S, et al. Amyloid blood biomarker detects Alzheimer’s disease. EMBO Mol Med. 2018;10:e8763.29626112
   PubMed Web of Science ®Google Scholar
• Ramusino MC, Garibotto V, Bacchin R, et al. Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47(2):270–280.31388720
   PubMed Web of Science ®Google Scholar
• Choi Y, Joh Y, Ryu JS, et al. Endogenous Aβ peptide promote Aβ oligomerization tendency of spiked synthetic Aβ in Alzheimer’s disease plasma. Mol Cell Neurosci. 2021;111:103588.33422673
   PubMed Web of Science ®Google Scholar